Explore all subjects

The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.Learn more about GLG's Compliance Framework


This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

GLG News by Neurologists

Analysis of: UCB's Vimpat(R) approved by U.S. FDA as adjunctive therapy for partial onset seizures in adults (www.pipelinereview.com)
FDA has approved lacosamide for add-on therapy of partial onset seizures.  It will be marketed by UCB under the brand name Vimpat.
Analysis of: National Trends in Psychotherapy by Office-Based Psychiatrists (archpsyc.ama-assn.org)
Unfortunately, many insurance payors do not realize that allowing psychotherapy visits may save the money in the long run by reducing the need for much more costly Inpatient psychiatric treatment. I find that my patients who receive psychotherapy are much less likely to miss work and much...
September 2, 2008
Azilect
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease (www.medicalnewstoday.com)
This is a well conceived study and totally convincing
Analysis of: ADAGIO Trial Results Show Teva's AZILECT(R) 1 Mg Tablets Slow Progression Of Parkinson's Disease (www.medicalnewstoday.com)
This large study shows that PD patients' severity of motor dysfunction is better on rasagiline than on placebo.
Analysis of: New Treatment Halts Progress of Alzheimer's Disease (www.abdn.ac.uk)
While the clinical trial data remain unpublished, those who attended the ICAD conference remain concerned about the possibility that the effects are not as pronounced as the interpretation by the investigators.
Analysis of: Doctors Say Medication Is Overused in Dementia (www.nytimes.com)
Medications used for realistic indications and with clinically appropriate symptomatic targets are indicated and provide effectiveness that additional staff cannot offer.  Decision making in health care is too often made by those who do not really provide clinical service but provide arm chair...
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Extavia® approved in E.U for treatment of multiple sclerosis, first in planned portfolio of therapies from Novartis (www.asia-manufacturing.com)
Extavia, Novartis' brand of  interferon beta 1b, has been approved for the  treatment of multiple sclerosis by the European Union.  With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009.  While essentially identical to Bayer's Betaferon interferon beta 1b,...
Daniel Wynn, MD, Director, Clinical Research
Daniel Wynn, MD, Director, Clinical Research
Consultants In Neurology Ltd.
Analysis of: Abbott Scientists Present A New Approach for Treating Attention-Deficit Hyperactivity Disorder (biz.yahoo.com)
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD.  The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Analysis of: Mixed Outcomes in Laparoscopy for Prostates (www.nytimes.com)
Surgeons adn patiets need to know that although laser TURP is an attractive and simple technique, patients may still need an alpha blocker to easily initiate voiding afterwards.  Further, later catheterization may be difficult due to pocket formation and thus blind-ending the catheter passage rather...
Analysis of: New Abbott Study of Investigational Vicodin CR(TM) Meets Primary Efficacy Endpoints in Phase III Trial (www.prnewswire.com)
The availability of any existing opioid molecule as a sustained-release preparation, eg Vicodin CR, is an advance in pain management.  That being said, however, there is little evidence that the risk of abuse or addiction is less with SR opioids.  In fact, the (usually) higher doses is SR...

Previous Page : 1 2 3 4 5 6 7 8 9 10 11 Next11 to 20 of 109

Analytics


Generated at 2009-01-07T19:00:58.307